HomeExplainersNobel Prize in Medicine 2026 Goes to Deisseroth, Hegemann and Nagel for...

Nobel Prize in Medicine 2026 Goes to Deisseroth, Hegemann and Nagel for Optogenetics, the Method That Controls Brain Cells With Light

Published on

4 min read

October 6: The 2026 Nobel Prize in Physiology or Medicine was awarded in Stockholm on Monday to Karl Deisseroth of Stanford University and the German scientists Peter Hegemann and Georg Nagel, “for their discoveries concerning light-gated ion channels and optogenetics”. Their work lets researchers switch individual nerve cells on and off with pulses of light, and it is now being tested as a way to give some sight back to people who have gone blind.

Update, October 6 (evening): The physics prize has gone to Francis Halzen for the IceCube Neutrino Observatory. Read: Nobel Prize in Physics 2026.

Key highlights

  • Winners: Karl Deisseroth (Stanford University and the Howard Hughes Medical Institute), Peter Hegemann (Humboldt University, Berlin) and Georg Nagel (University of Würzburg).
  • Prize: 12 million Swedish kronor, about $1.2 million, shared between the three.
  • The science: A light-sensitive protein from algae is put into nerve cells, which can then be controlled with light.
  • Medicine: A gene therapy for the eye disease retinitis pigmentosa is under review by the US Food and Drug Administration.
  • Left out: Several early contributors, among them Ed Boyden and Zhuo-Hua Pan. The prize can go to three people at most.

What optogenetics is

In the early 2000s Hegemann and Nagel found channelrhodopsin, a protein in the green alga Chlamydomonas that opens a channel in the cell’s membrane when light falls on it. In 2005 Deisseroth’s laboratory put the gene for that protein into nerve cells and showed that blue light could make them fire. By 2007 his team was switching nerve cells on and off in the brains of living mice.

“Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of,” said Per Svenningsson, Chair of the Nobel Committee for Physiology or Medicine, in the official announcement. Researchers use it to work out which cells and circuits are involved in memory, sleep and behaviour, and in neurological and psychiatric disorders.

From the lab to the eye clinic

The first medical use is in the eye. Nanoscope Therapeutics has developed a single injection that delivers a light-sensitive protein to cells in the retina of people with retinitis pigmentosa. The company has said the US Food and Drug Administration accepted its application in September 2026. If approved, it would be the first optogenetic therapy on the market. Ray Therapeutics and the French company GenSight Biologics are testing similar approaches.

Who was left out

Nobel rules allow at most three winners, and more than three people helped to create optogenetics. Scientists whose early work is often cited include Ed Boyden of MIT, first author of Deisseroth’s 2005 paper; Zhuo-Hua Pan of Wayne State University; the Austrian scientist Gero Miesenböck, who made nerve cells respond to light by genetic means in 2002; and the biophysicist Ernst Bamberg, a co-author of the early channelrhodopsin papers with Nagel and Hegemann. The Nobel Assembly does not explain its choices, and its nomination records stay sealed for 50 years.

The Asia angle: the scientist who got there first

Zhuo-Hua Pan began his research career in China and moved to the United States in the 1980s for his doctorate. Pan has said that by February 2004 he had made nerve cells from the retina respond to light using channelrhodopsin, months before the experiment in Deisseroth’s laboratory that led to the 2005 paper, and that journals turned his paper down before it was accepted. It appeared in the journal Neuron in April 2006, eight months after the Stanford paper.

Pan is a vision scientist, and his experiment was done in cells of the retina, the tissue in which the first therapy is now being tested. The second author of the 2005 Stanford paper was Feng Zhang, who later became known for his work on the gene-editing tool CRISPR.

Timeline

WhenWhat happened
2002–2003Nagel, Hegemann and colleagues describe channelrhodopsin from green algae
2002Miesenböck makes nerve cells sensitive to light by genetic means
August 2005The Stanford paper is published in Nature Neuroscience
April 2006Pan’s paper is published in Neuron
2007Deisseroth’s team controls nerve cells in living mice
September 2026The US regulator accepts the first application for an optogenetic therapy
5 October 2026Nobel Prize awarded

Compiled by The Press of Asia from the Nobel Assembly’s announcement and published research.

What comes next

The three laureates will receive the prize in Stockholm on 10 December, the anniversary of Alfred Nobel’s death. Watch also for the US regulator’s decision on the first optogenetic eye therapy, which would move the method from the laboratory into routine medicine.

Sources

Written by
International Desk

The International Desk covers world and Asian affairs, diplomacy and conflict, with a focus on what they mean for India. Stories are checked against at least two credible sources before publication.

Latest News

Latest News

UN E-Government Survey 2026 Puts AI Agents, Human Oversight and Digital Divides in Focus

The UN’s 2026 e-government survey examines a shift towards agentic public services, while highlighting connectivity gaps, usability and human oversight.

Trump, Xi and Putin Issue Shenzhen Declaration on Nuclear Risks and Energy Supply

The three leaders’ Shenzhen declaration addresses nuclear risks, energy flows and UN reform. It does not announce a ceasefire or a nuclear reduction treaty.

Vietnam Takes Over APEC 2027 Host Role, With Phu Quoc Set for Leaders’ Week

Vietnam formally received the APEC 2027 host role from China in Shenzhen. Phu Quoc will host the culminating leaders’ week.

Hong Kong’s John Lee Courts Peru Trade and Singapore Technology Investment at APEC

John Lee met Peru’s Keiko Fujimori and Singapore’s Lawrence Wong at APEC, promoting an existing FTA and technology investment opportunities.

Related Coverage

Hong Kong and Chile Sign Working Holiday Deal: 100 Places a Year, Visa Details Awaited

A new Hong Kong–Chile working holiday agreement provides 100 places annually on each side and stays of up to 12 months. Application details are still awaited.

India and Japan Expand Cybersecurity and Space Cooperation at Tokyo 2+2 Talks

India and Japan’s fourth 2+2 meeting in Tokyo focused on AI-related cybersecurity, space cooperation and security coordination across the Indo-Pacific.

Philippines and Chile Sign CEPA, Opening a New Trade Route to Latin America

The Philippines and Chile signed their CEPA at APEC. The pact is Manila’s first bilateral free trade agreement with a Latin American country.